| Identification | Back Directory | [Name]
Bexarotene-d4 | [CAS]
2182068-00-2 | [Synonyms]
LGD1069 D4
Bexarotene-d4
Bexarotene-d4
DISCONTINUED, offer alternates | [Molecular Formula]
C24H24D4O2 | [MDL Number]
MFCD21363455 | [MOL File]
2182068-00-2.mol | [Molecular Weight]
352.503 |
| Chemical Properties | Back Directory | [solubility ]
DMF: 20 mg/ml; DMF:PBS (pH 7.2)(1:3): 0.25 mg/ml; DMSO: 10 mg/ml; Ethanol: 0.5 mg/ml | [form ]
A crystalline solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Bexarotene-d4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5]. | [References]
[1] Vakeva L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2012 May;92(3):258-63. doi: 10.2340/00015555-1359. DOI:10.2340/00015555-1359
[2] Gui Y, et al. Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1. J Pain. 2019 Jan 17. pii: S1526-5900(18)30607-2. DOI:10.1016/j.jpain.2019.01.007
[3] Zhang X, Schlaak M, Fabri M, Mauch C, Kurschat P. Successful Treatment of a Panniculitis-Like Primary Cutaneous T-Cell Lymphoma of the α/β Type with Bexarotene. Case Rep Dermatol. 2012 Jan;4(1):56-60. DOI:10.1159/000337433
[4] Orendas P, Kubatka P, Kajo K, Stollarova N, Kassayova M, Bojkova B, Pec M, Nosal V, Kiskova T, Zihlavnikova K, Karsnakova R. Melatonin enhanced bexarotene efficacy in experimental mammary carcinogenesis. Neoplasma. 2012;59(4):469-74. DOI:10.4149/neo_2012_060
[5] Cras A, Politis B, Balitrand N, Darsin-Bettinger D, Boelle PY, Cassinat B, Toubert ME, Chomienne C. DOI:10.1158/1078-0432.CCR-11-0510 |
|
|